Some experts believe that there is enough evidence to support the association of BRAF V600E with aggressive clinicopathologic features, including extrathyroidal extension, lymph node metastases, recurrence, mortality, and resistance to radioactive iodine, suggesting a valuable role in risk stratification and guiding treatment decisions (8). This evidence concerns the gene BRAF and metastatic malignant neoplasm in the lymph nodes.